Preparing clinical grade Ag-specific T cells for adoptive immunotherapy trials
- 1 January 2007
- journal article
- review article
- Published by Elsevier in Cytotherapy
- Vol. 9 (7) , 613-629
Abstract
The production of clinical-grade T cells for adoptive immunotherapy has evolved from the ex vivo numerical expansion of tumor-infiltrating lymphocytes to sophisticated bioengineering processes often requiring cell selection, genetic modification and other extensive tissue culture manipulations, to produce desired cells with improved therapeutic potential. Advancements in understanding the biology of lymphocyte signaling, activation, homing and sustained in vivo proliferative potential have redefined the strategies used to produce T cells suitable for clinical investigation. When combined with new technical methods in cell processing and culturing, the therapeutic potential of T cells manufactured in academic centers has improved dramatically. Paralleling these technical achievements in cell manufacturing is the development of broadly applied regulatory standards that define the requirements for the clinical implementation of cell products with ever-increasing complexity. In concert with academic facilities operating in compliance with current good manufacturing practice, the prescribing physician can now infuse T cells with a highly selected or endowed phenotype that has been uniformly manufactured according to standard operating procedures and that meets federal guidelines for quality of investigational cell products. In this review we address salient issues related to the technical, immunologic, practical and regulatory aspects of manufacturing these advanced T-cell products for clinical use.Keywords
This publication has 135 references indexed in Scilit:
- Enhanced Antitumor Activity of T Cells Engineered to Express T-Cell Receptors with a Second Disulfide BondCancer Research, 2007
- The Continuing Contribution of Gene Marking to Cell and Gene TherapyMolecular Therapy, 2007
- Integrating DNA Vectors For Gene TherapyMolecular Therapy, 2007
- A Phase I Study on Adoptive Immunotherapy Using Gene-Modified T Cells for Ovarian CancerClinical Cancer Research, 2006
- Cancer Regression in Patients After Transfer of Genetically Engineered LymphocytesScience, 2006
- Enhanced Antitumor Activity of Murine-Human Hybrid T-Cell Receptor (TCR) in Human Lymphocytes Is Associated with Improved Pairing and TCR/CD3 StabilityCancer Research, 2006
- CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein–Barr virus-specific effector memory T cellsClinical and Experimental Immunology, 2006
- Structure-based prediction of insertion-site preferences of transposons into chromosomesNucleic Acids Research, 2006
- Simultaneous Generation of CD8+ and CD4+ Melanoma-Reactive T Cells by Retroviral-Mediated Transfer of a Single T-Cell ReceptorCancer Research, 2005
- Lineage relationship and protective immunity of memory CD8 T cell subsetsNature Immunology, 2003